Hospitalization of hyperglycemic lung cancer patients during treatment

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9560-9560
Author(s):  
B. E. Martin ◽  
F. Mott ◽  
J. Song
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Significant Risk ◽  
Serum Glucose ◽  
Chemotherapy Cycle ◽  
Baseline Serum ◽  
Lung Cancer Patients ◽  
Treatment Data ◽  
Grade 3 ◽  
Cancer Experience

9560 Background: Approximately 20 million Americans have type 2 diabetes mellitus. This same group is at significant risk of developing malignancy. Evidence suggest that diabetics with colon and breast cancer experience inferior treatment outcomes. There are few direct comparisons of treatment outcome and/or treatment tolerability in those with and without hyperglycemia. There are no such comparisons in lung cancer patients. We anticipate those with hyperglycemia will tolerate treatment less well than those with euglycemia. With this premise, we assessed hospitalization risk between lung cancer patients with normal or elevated baseline serum glucose (BSG) prior to initial chemotherapy cycle. Methods: After obtaining institutional IRB approval, tumor registry analysis identified 364 consecutive individuals diagnosed with lung cancer between 2005 and 2007 at our institution. One hundred and fifteen were excluded: 71 not treated, 17 duplicate entries, 16 stage 1A lung cancer, 8 missing data, 2 glucose under 60 mg/dl, 1 admitted for chemotherapy. Demographic and cancer specific data were obtained from the registry. Chart review yielded: BSG, date of first chemotherapy cycle, date of hospitalization, neutrophil count at admission, radiation therapy 30 days before/after treatment. Data presented was analyzed using multivariate logistic regression. We utilized WHO strata for fasting whole blood glucose measurements. Those presenting with grade 3 (or greater) neutropenia were excluded. Results: See Table . Conclusions: Lung cancer patients with hyperglycemia are more likely to be hospitalized in the 30 days following their first cycle of cytotoxic chemotherapy. We used the WHO glucose strata to analyze our data. Compared to those with normal BSG, those with BSG between 110 and 126 mg/dl were twice as likely to be hospitalized, and those with BSG over 126 mg/dl had four times the risk. We feel this simple metric will improve clinician's treatment decisions. Prospective analysis of diabetic cancer outcomes is needed. [Table: see text] No significant financial relationships to disclose.

scholarly journals Risk factors for radiation pneumonitis in lung cancer patients with subclinical interstitial lung disease after thoracic radiation therapy

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Fangjuan Li ◽  
Hui Liu ◽  
Hongyu Wu ◽  
Shixiong Liang ◽  
Yaping Xu
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Significant Risk ◽  
Intensity Modulated Radiation Therapy ◽  
Significant Risk Factor ◽  
Lung Cancer Patients ◽  
Thoracic Radiation ◽  
Mean Lung Dose ◽  
Grade 3

Abstract Background Previous studies have found that patients with subclinical interstitial lung disease (ILD) are highly susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. In the present study we aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy in lung cancer patients with subclinical ILD. Methods We retrospectively analyzed data from lung cancer patients with subclinical ILD who were treated with thoracic intensity-modulated radiation therapy with a prescribed dose of ≥ 50 Gy in our institution between January 2016 and December 2017. Results Eighty-seven consecutive lung cancer patients with subclinical ILD were selected for the study. The median follow-up period was 14.0 months. The cumulative incidence of grades ≥ 2 and ≥ 3 RP at one year was 51.0% and 20.9%, respectively. In the multivariate analysis, a mean lung dose ≥ 12 Gy was a significant risk factor for grade ≥ 2 RP (p = 0.049). Chemotherapy with gemcitabine in the past, V5 ≥ 50%, and subclinical ILD involving ≥ 25% of the lung volume were significantly associated with grade ≥ 3 RP (p = 0.046, p = 0.040, and p = 0.024, respectively). Conclusion Mean lung dose is a significant risk factor for grade ≥ 2 RP. Lung cancer patients who have received chemotherapy with gemcitabine in the past, V5 ≥ 50%, and those with subclinical ILD involving ≥ 25% of lung volume have an increased risk of grade ≥ 3 RP in lung cancer patients with subclinical ILD.

scholarly journals Risk Factors for Radiation Pneumonitis in Lung Cancer Patients with Subclinical Interstitial Lung Disease after Thoracic Radiation Therapy

2021 ◽  
Author(s):  
Fangjuan Li ◽  
Hui Liu ◽  
Hongyu Wu ◽  
Shixiong Liang ◽  
Yaping Xu
Keyword(s):  
Lung Cancer ◽  
Radiation Therapy ◽  
Cancer Patients ◽  
Radiation Pneumonitis ◽  
Significant Risk ◽  
Significant Risk Factor ◽  
Lung Cancer Patients ◽  
The Past ◽  
Thoracic Radiation ◽  
Grade 3

Abstract Background: Previous studies have found that patients with subclinical interstitial lung disease (ILD) are more susceptible to developing radiation pneumonitis (RP) after thoracic radiation therapy. The present study aimed to evaluate the incidence of and risk factors for RP after thoracic intensity-modulated radiation therapy (IMRT) in lung cancer patients with subclinical ILD.Methods: We retrospectively analyzed lung cancer patients with subclinical ILD who were treated with thoracic IMRT with a prescribed dose of ≥50 Gy in our institutions between January 2016 and December 2017.Results: A total of 87 consecutive lung cancer patients with subclinical ILD were selected for the study. The cumulative incidence of grades ≥2 and ≥3 RP at one year was 51.0% and 20.9%, respectively. In the multivariate analysis, the mean lung dose (MLD) ≥12Gy was a significant risk factor for grade ≥2 RP (p = 0.049). Chemotherapy with gemcitabine in the past，V5≥50%，and subclinical ILD involving ≥25% of lung volume were significantly associated with grade ≥3 RP (p = 0.046, p = 0.040, and p = 0.024, respectively).Conclusion: MLD is a significant risk factor for grade ≥2 RP. Lung cancer patients who have received chemotherapy with gemcitabine in the past, V5, and those with subclinical ILD involving ≥25% of lung volume have an increased risk of grade ≥3 RP in lung cancer patients with subclinical ILD.

scholarly journals Multiple Analytical Approaches Demonstrate a Complex Relationship of Genetic and Nongenetic Factors with Cisplatin- and Carboplatin-Induced Nephrotoxicity in Lung Cancer Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
H. Eugene Liu ◽  
Kuan-Jen Bai ◽  
Yu-Chen Hsieh ◽  
Ming-Chih Yu ◽  
Chun-Nin Lee ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lung Cancer ◽  
Cancer Patients ◽  
Kidney Function ◽  
Framingham Study ◽  
Baseline Serum ◽  
Lung Cancer Patients ◽  
Cart Analysis ◽  
Prediction Rate ◽  
Analytical Approaches

Background. Cisplatin and carboplatin cause nephrotoxicity by forming platinum-DNA adducts and lead to cell death.Methods. One-hundred and sixteen Taiwanese lung cancer patients who received cisplatin or carboplatin more than twice were recruited, and their genotypes were determined. The risk of renal dysfunction, injury to the kidney, failure of kidney function, loss of kidney function, and end-stage kidney disease (RIFLE) criteria were used to evaluate the occurrence of nephrotoxicity. A logistic regression, multiple regression with a classification and regression tree (CART), and the Framingham study risk score were used to analyze interactions between genetic and nongenetic factors in producing platinum-induced nephrotoxicity.Results.ERCC1118C andTP5372Arg polymorphisms were associated with increased risks of platinum-induced nephrotoxicity. Other risk factors found included the platinum type, baseline serum creatinine (Scr), coadministration of vinorelbine, and the number of chemotherapy cycles. The overall prediction rate of the CART was 82.7%, with a sensitivity of 0.630 and specificity of 0.896. The Framingham study risk prediction model contained 7 factors. Its prediction rate was 84.5%, with a sensitivity of 0.643 and specificity of 0.909.Conclusions. Genetic polymorphisms ofERCC1andTP53are risk factors for nephrotoxicity. The CART analysis may provide a clinically applicable model to predict the risk of cisplatin- and carboplatin-induced nephrotoxicity.

scholarly journals The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer

2014 ◽  
Vol 2014 ◽  
pp. 1-9 ◽  
Author(s):  
Bohdan Kadlec ◽  
Jana Skrickova ◽  
Zdenek Merta ◽  
Ladislav Dusek ◽  
Jiri Jarkovsky
Keyword(s):  
Quality Of Life ◽  
Lung Cancer ◽  
Venous Thromboembolism ◽  
Life Expectancy ◽  
Cancer Patients ◽  
Elevated Risk ◽  
Thromboembolic Events ◽  
Lung Cancer Patients ◽  
Cancer Experience

Patients with lung cancer experience elevated risk of venous thromboembolism. Cancer patients with thrombosis have a shorter life expectancy and the occurrence of VTE worsens the quality of life and may delay, interrupt, or completely halt the cancer therapy. In a large cohort of lung cancer patients we monitored the incidence of venous thromboembolism and we identified groups of patients with the highest risk of venous thromboembolism suitable for antithrombotic prophylaxis, which could favourably affect their morbidity and mortality.

scholarly journals Polymorphisms in ERCC1 and Grade 3 or 4 Toxicity in Non–Small Cell Lung Cancer Patients

2005 ◽  
Vol 11 (4) ◽  
pp. 1534-1538 ◽  
Author(s):  
Rebecca Suk ◽  
Sarada Gurubhagavatula ◽  
Sohee Park ◽  
Wei Zhou ◽  
Li Su ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancer Patients ◽  
Grade 3

scholarly journals Associations ofLIG4andHSPB1Genetic Polymorphisms with Risk of Radiation-Induced Lung Injury in Lung Cancer Patients Treated with Radiotherapy

2015 ◽  
Vol 2015 ◽  
pp. 1-6
Author(s):  
Feng Xu ◽  
Ji-Chang Han ◽  
Ya-Jun Zhang ◽  
Yi-Jie Zhang ◽  
Xiao-Chun Liu ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Injury ◽  
Cancer Patients ◽  
Genetic Polymorphisms ◽  
Genotype Distribution ◽  
Chi Square ◽  
Lung Cancer Patients ◽  
Significant Difference ◽  
Radiation Induced ◽  
Grade 3

Objective.This study aims to explore the correlations of genetic polymorphisms inLIG4andHSPB1genes with the radiation-induced lung injury (RILI), especially radiation pneumonitis (RP), in lung cancer patients.Methods.A total of 160 lung cancer patients, who were diagnosed with inoperable lung cancer and received radiotherapy, were included in the present study from September 2009 to December 2011. TaqMan Real-Time PCR (RT-PCR) was used to verify the SNPs ofLIG4andHSPB1genes. Chi-square criterion was used to compare the differences in demographic characteristics, exposure to risk factors, and SNPs genotypes. Crude odds ratios (ORs) with 95% confidence intervals (95% CI) were calculated by logistic regression analysis. All statistical analyses were conducted in SPSS 18.0.Results.A total of 32 (20.0%) lung cancer patients had RP after receiving radiotherapy. Of the 32 cases, 4 cases were of grade 2, 24 cases were of grade 3, and 4 cases were of grade 4. However, our results indicated that the general condition and treatment of all patients had no significant difference with RP risk(P>0.05). Meanwhile, our results revealed that there was no significant association between the frequencies ofLIG4 rs1805388andHSPB1 rs2868371genotype distribution and the risk of RP(P>0.05).Conclusion.In conclusion, we demonstrated that the genetic polymorphisms inLIG4 rs1805388andHSPB1 rs2868371were not obviously correlated with the risk of RP and RILI of lung cancer.

scholarly journals Profile of Lung Cancer: A One-Year Report

1970 ◽  
Vol 12 (2) ◽  
pp. 115-119
Author(s):  
Parveen Shahida Akhtar ◽  
Zafor Mohammad Masud ◽  
Mohammad Tarek Alam ◽  
Maksuda Begum
Keyword(s):  
Lung Cancer ◽  
Cell Carcinoma ◽  
Cancer Patients ◽  
Metastatic Cancer ◽  
Performance Status ◽  
Symptomatic Treatment ◽  
Who Grade ◽  
Lung Cancer Patients ◽  
Grade 3 ◽  
One Year

Background: Lung cancer has been the most common cancer in the world since 1985 and the leading cause of cancer death. Worldwide it is by far the most common cancer of men and increasingly being recognized in Bangladesh. Objective: To observe the profile of lung cancer patients and the outcome of chemotherapy. Method: In one year (1st January’08 to 31st December’08) the lung cancer patients who attended the dept. of Medical Oncology were included in this study. The patient’s history, clinical evaluation, previous treatment record (surgical intervention, chemotherapy and radiotherapy), histopathology and other investigation reports were documented. Chemotherapy and or supportive and symptomatic treatment carried out in the department were noted and response of the treatment were observed and documented. Result: Total number of patients was 701.Of them, 608 males and 93 females; male female ratio: 6.53:1. Common occurrence (> 85%) at and above 50 years of old; age range 25 years to 95 years and mean age 62 years; 44% was illiterate and 40% had primary school education; more than 82% belonged to poor and bellow average socioeconomic status. Previous records showed 524 patients (about 75%) attended after diagnosis and 177 cases (25%) had had prior treatment (6 by surgery, 22 by radiotherapy and 147 by chemotherapy). On clinical evaluation, almost all patients were symptomatic with WHO Grade-2 (44.51%) and Grade -3 (26.68%) performance status. Right lung was affected more (55%). Pathologically non-small cell carcinoma was 81.45% and small cell carcinoma 18.55%. But histopathology differed by sex; squamous cell carcinoma (43.42%) was most common in male but in female it was adenocarcinoma (55.92%). All most all cases were at inoperable stage (locally advanced/metastatic cancer/ medically unfit). Thirty percent of male patients and 45% of females dropped out after first and second visit. Around 20% patients got only supportive symptomatic management in both sexes and 326 patients (296 male and 30 female) were treated by chemotherapy. Within three to six months of treatment, 10% of the patients showed complete symptomatic relief, weight gaining and radiological disappearance of tumor and all most all patients benefited of some sorts of symptoms relief. Conclusion: The lung cancer patients were at inoperable stages with WHO Grade 2 and Grade 3 performance status in most of the cases; needed much more supportive and symptomatic treatment. Chemotherapy was effective; complete clinical and radiological response in 10% of cases and others got benefit with some sorts of symptoms relief and radiological improvement. Keyword: Lung cancer, Bangladesh, squamous cell carcinoma, adenocarcinoma metastatic cancer, Chemotherapy, Bangladesh. DOI: http://dx.doi.org/10.3329/jom.v12i2.8417 JOM 2011; 12(2): 115-119

Weight Loss Associated with Platinum-Based Chemotherapy in Patients with Advanced Lung Cancer

Chemotherapy ◽  
2016 ◽  
Vol 61 (5) ◽  
pp. 256-261 ◽  
Author(s):  
Kayoko Morio ◽  
Toshiyuki Minami ◽  
Takashi Sozu ◽  
Kazuyuki Niki ◽  
Takashi Kijima ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Weight Loss ◽  
Cancer Patients ◽  
Therapeutic Effect ◽  
Treatment Completion ◽  
Advanced Lung Cancer ◽  
Completion Rates ◽  
Lung Cancer Patients ◽  
Platinum Based Chemotherapy ◽  
Grade 3

Background: We examined whether the weight loss that occurs with platinum-based chemotherapy in lung cancer patients is associated with chemotherapy side effects, treatment completion rates and therapeutic effect. Methods: We retrospectively reviewed charts of advanced lung cancer patients treated with ≥2 cycles of platinum-based chemotherapy. Patients were divided into 2 groups based on ≥5 or <5% weight loss. Relationships between weight loss and other variables were investigated. Results: Among 114 patients, 18 (15.8%) experienced ≥5% weight loss. Significantly more patients with small-cell lung cancer (SCLC) than with non-SCLC were found to have ≥5% weight loss (30.8 vs. 11.4%, p = 0.023). Patients with ≥5% weight loss experienced higher incidences of grade 3-4 leukopenia (p = 0.008) and neutropenia (p = 0.005), and treatment completion rates were lower in this group (p = 0.035). Weight loss was not significantly associated with therapeutic effect. Conclusion: The weight loss in patients with advanced lung cancer receiving platinum-based chemotherapy is associated with SCLC, grade 3-4 leukopenia, neutropenia and a decrease in treatment completion rate.

Sign in / Sign up

Export Citation Format

Share Document